• Lunit and collaborators demonstrate the predictive value and analytical prowess of Lunit's AI-biomarker platform in a wide range of cancer types and clinical practices

Lunit, a leading global provider of AI-powered cancer diagnostic solutions, today announced the presentation of 16 abstracts featuring its AI-biomarker platform at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, Illinois, on June 2-6.

Since 2019, the company has been releasing groundbreaking findings based on its AI-powered tissue analysis platform, Lunit SCOPE, at the ASCO annual meeting. At this year's ASCO, Lunit plans to showcase the largest number of studies in the company's history, including 10 poster presentations and 6 online publications. The studies will cover a range of topics, from predicting clinical outcomes to analyzing tumor microenvironments in various cancer types using the Lunit SCOPE suite.

Some of Lunit's highlighted abstracts at ASCO 2023 include:

• A study conducted in collaboration with the National Cancer Center Hospital East (NCCE) found a correlation between tumor-infiltrating lymphocyte (TIL) density change during chemoradiotherapy (CRT) and pathologic complete response (pCR) rate in locally advanced rectal cancer (LARC), indicating the potential of Lunit SCOPE IO to predict favorable outcomes

• Lunit SCOPE IO analyzed TILs in head and neck squamous cell carcinoma (HNSCC) patients treated with durvalumab +/- tremelimumab, showing improved outcomes due to increased immune inflammation

• Lunit SCOPE IO validated the efficacy of neoadjuvant HPV vaccine and immunotherapy of HPV+ head and neck squamous cell carcinoma (HNSCC) patients

• A collaborative study led by Mayo Clinic predicted prognosis in patients with colon cancer by applying AI-derived immune phenotypes

• A study showing how Lunit SCOPE IO predicts the efficacy of immunotherapy based on the patient's Transforming growth factor-beta (TGFβ) level

• The use of Lunit SCOPE IO to predict MET pathogenic mutations in non-small cell lung cancer

• The use of Lunit SCOPE UIHC (Universal Immunohistochemistry) for exploring target cancer types and predicting response to novel tumor-associated antigens (TAA) targeted agents

• Using AI to analyze the spatial arrangement of macrophages within tumor environments and how it relates to the Interferon Gamma (IFNG) signature and immune phenotype across different types of cancer

"We are thrilled to showcase the largest number of studies in the company’s history at ASCO 2023, demonstrating Lunit SCOPE’s efficacy," said Brandon Suh, CEO of Lunit. "Through our novel academic research using Lunit SCOPE suite across various cancer types and treatment settings, we aim to bring cutting-edge technology to the forefront of optimized cancer treatment for all patients."

Visit team Lunit at Booth IH21. Reach out to schedule a meeting at (oncology@lunit.io).